Xarelto Paediatric VTE PASS Drug Utilization Study: An Observational, Longitudinal, Multi-source Drug Utilization Safety Study to Evaluate the Drug Use Patterns and Safety of Rivaroxaban Oral Suspension in Children Under Two Years With Venous Thromboembolism

This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).
VTE is a condition in which blood clots form in the veins, usually in the leg. This can cause pain and swelling. The clot can also break apart and travel in the blood to the lungs where it can block the blood flow. This can be life threatening.
Rivaroxaban is approved for doctors to prescribe to children with VTE, but there is limited information about how it is used, how well it works, and how safe it is in children under 2 years old. Children in this study are already receiving or will receive rivaroxaban or other currently used medicines for VTE from their doctor according to the approved product information.
The purpose of this study is to collect information on the pattern of use and safety of rivaroxaban and other standard medicines for VTE in children under 2 years old.
The main information that researchers will collect in this study:
* Age, gender, and other information about the child and their illness
* Type of VTE treatment given to the child
* Occurrence of medically important bleeding and its severity
Further information that researchers will collect:
* Changes in the characteristics of the children given VTE treatment (e.g., changes in the age range of children given VTE treatment) and changes in the treatment pattern for VTE
* Return of VTE symptoms
* Types of doctors who prescribe VTE treatment and their set-up (e.g., special clinics versus hospitals) Besides this data collection, no further tests or examinations are needed in this study.
The data for this study will be collected from electronic health records and health insurance claims data until 2026.
Researchers will observe each child during treatment until:
* end of the anticoagulation treatment period e.g. discontinuation of all study drugs,
* their information is no longer available, or
* the study ends.

开始日期2027-09-01

申办/合作机构

Bayer AG

[+1]

NCT07246005

/ Not yet recruiting临床2期

A Randomised Pilot Study Assessing the Optimal Duration of Anticoagulation for Left Ventricular Thrombus

The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of anticoagulation in the treatment of LV thrombus. The main objectives of the study are:
* To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement.
* To identify the optimal length of anticoagulation in the treatment of LV Thrombus
After randomisation participants will:
* Continue their prescribed oral anticoagulant for the remainder of the trial
* Discontinue their prescribed oral anticoagulant for the remainder of the trial

开始日期2026-12-01

申办/合作机构

Queen Mary University of London

NCT07468448

/ Not yet recruiting临床3期IIT

Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)

CATIS-ICAS is a double-blind, randomized, placebo-controlled (RCT), phase III study seeking to demonstrate that oral rivaroxaban 2.5 mg twice daily plus aspirin daily is superior to clopidogrel 75 mg daily plus aspirin daily for 90 days followed by placebo plus aspirin daily for preventing recurrent stroke in those with ischemic stroke secondary to intracranial atherosclerotic disease (ICAD) of 30-99%, when started within 30 days of index stroke.

开始日期2026-09-30

申办/合作机构

Population Health Research Institute

100 项与利伐沙班相关的临床结果

登录后查看更多信息

100 项与利伐沙班相关的转化医学

登录后查看更多信息

100 项与利伐沙班相关的专利（医药）

登录后查看更多信息

7,983

项与利伐沙班相关的文献（医药）

2027-01-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Multi-phonon quantitation of rivaroxaban by broadband THz spectroscopy

Article

作者: Jin, Zuanming ; Wu, Xu ; Pei, Fei ; Zhu, Yiming ; Zhang, Jinjing ; Zhao, Chenyu ; Peng, Yan ; Zhou, Hong ; Liu, Hanwen ; Chen, Zinuo ; Tian, Qingchong

Accurate quantification of low-dose crystalline active pharmaceutical ingredients (APIs) remains a critical challenge. Conventional methods, including high-performance liquid chromatography with ultraviolet detection, powder X-ray diffraction, and transmission Raman spectroscopy, often suffer from limited lattice specificity, insufficient sensitivity, or destructive measurement. Here we present a multi-phonon quantitation strategy based on broadband THz spectroscopy (6-13 THz), using rivaroxaban as a representative low-dose API. Periodic DFT calculations on an XRD-validated crystal structure, complemented by isolated-molecule DFT calculations, to establish the lattice and molecular motions underlying the observed THz peaks. The simulated THz spectrum reproduces the experimental result with a mean absolute deviation of 0.06 THz. The three dominant peaks are assigned to physically distinct vibrational modes: an intramolecular vibration (8.93 THz) and two intermolecular lattice phonons (10.49 and 11.82 THz), with H-bond oscillation amplitudes of 0.069-0.125 Å. With these results, peak-area fusion (ΣA) across these modes achieves a limit of quantification (LoQ) of 98.1 μg, which is 25.3% lower than that of the best individual peak-area model and 10.6-fold lower than that of transmission Raman spectroscopy. Peak-height ratios among the three modes showed limited variation with analyte mass under the present measurement conditions, providing an internal consistency check. Overall, this study demonstrates that physically resolved THz phonons can be combined to enhance quantitative sensitivity in a crystalline API model system.

2026-12-31·SCANDINAVIAN CARDIOVASCULAR JOURNAL

A Scandinavian perspective of the projected lifetime cost-effectiveness of rivaroxaban plus aspirin in the COMPASS trial

Article

作者: Ryden, Lars ; Lamy, Andre ; Eikelboom, John W. ; Tong, Wesley ; Yuan, Fei

Objectives. Rivaroxaban 2.5 mg twice daily with aspirin 100 mg daily was superior to aspirin 100 mg daily in the COMPASS trial but the cost-effectiveness in Scandinavia is unknown. Design. Mean lifetime costs (USDs) and quality-adjusted life-years were determined from a Scandinavian perspective using a 2-state Markov model with US mortality data. Subgroup and sensitivity analyses were performed. Results. Over a lifetime adding rivaroxaban to aspirin had lower costs (-$3791USD/-23675DKK/-27410NOK/-29200SEK) and gained 1.17 QALYs versus ASA alone. Conclusion. Rivaroxaban 2.5 mg twice daily with aspirin is a dominant strategy compared to aspirin alone in COMPASS participants from a Scandinavian perspective.

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in a Belgian healthcare setting

Article

作者: Salter, Chloe ; Stawowczyk, Ewa ; Subash, Rupesh ; Goovaerts, Hannah ; Ricci-Pacifici, Luca ; Dickerson, Carissa

AIMS:

Direct oral anticoagulants (DOACs) are recommended for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation (NVAF) in preference to vitamin K antagonists (VKAs, e.g. warfarin). This study assessed the cost-effectiveness of apixaban versus warfarin, dabigatran, edoxaban, and rivaroxaban for patients with NVAF from the Belgian payer perspective.

METHODS:

Based on a previously-validated model, a lifetime cohort-level Markov model was built in Microsoft Excel for the Belgian setting, incorporating costs (2025) representative of a DOAC market following patent expiry. The cohort (n = 1,000) included patients with NVAF eligible for oral anticoagulation. Different study types provided clinical inputs for event risk in the base case analysis (based on a network meta-analysis of randomised controlled trials) and in a scenario analysis (based on real-world evidence). The primary model outcome was the incremental cost-effectiveness ratio (ICER), measured by the cost per quality-adjusted life year (QALY) gained. Cost-effectiveness was determined by a willingness-to-pay threshold of €30,000/QALY gained.

RESULTS:

Driven by a reduction in clinical event risk, apixaban treatment was associated with QALY gains of 0.306, 0.068, 0.115 and 0.034 compared with warfarin, dabigatran, edoxaban, and rivaroxaban, respectively. In the base case analysis, apixaban treatment was associated with lower total costs due to a reduction in acute event costs and long-term management costs, resulting in apixaban dominating (i.e. more effective and less costly) all comparators from a Belgian payer perspective. Similar conclusions were observed in a scenario analysis using clinical inputs derived from real-world evidence.

CONCLUSIONS:

Apixaban is associated with fewer clinical events and lower total costs versus warfarin, dabigatran, edoxaban, and rivaroxaban for patients with NVAF, dominating (i.e. more effective and less costly) all comparators from a Belgian payer perspective under post-patent-expiry assumptions. The consistency of model outcomes between base case and scenario analyses suggests a level of robustness to these findings.

1,427

项与利伐沙班相关的新闻（医药）

2026-10-08

·新华报业网

上海汇伦医药董竹：不做“放之四海皆准”的渠道，以双渠道协同锚定增长

2026 年的中国医药产业，正站在创新与转型的十字路口：一方面，创新药研发进入集中收获期，国家药监局《2025年度药品审评报告》显示，2025年全年批准1类创新药 76 个，创历史新高；另一方面，药品流通渠道深刻重构，互联网医疗、医药电商、DTP 专业药房等新业态加速分流传统医院终端市场，“院内萎缩就全面转向院外”成为行业热议话题。上海汇伦医药股份有限公司(以下简称“汇伦医药”)执行董事董竹给出的答案，是“两条腿走路”。董竹表示，渠道策略不能一刀切，需要一套多维度筛选漏斗；而未来三年的增长，将锚定多款已上市或即将上市的核心品种。一、从研发到销售：一套渠道方法论的由来这套方法论源自董竹横跨前后端的职业轨迹。2019年加入汇伦医药后，董竹先从临床研究工作做起，随后逐步拓展至企业经营及业务管理。自2024年3月起，他负责公司综合业务部及OTC业务部的整体运营与管理。院外市场彼时刚刚打开，摆在团队面前的路径很多——院外线下门店、社区药店、线上购药平台，资源投入与产出逻辑各不相同。“我们没有盲目跟风行业的普遍路径，通常是站在产品特性和用户特性的角度做分析。”董竹进一步以2mg地诺孕素片为例解释：作为治疗子宫内膜异位症的专科用药，该产品需长期每日服用、可替代性低，天然匹配电商的批量备货与便捷性逻辑；2mg规格的地诺孕素片，核心受众为20—50岁女性，恰是电商消费主力人群。市场验证了这一判断：公司地诺孕素片在院外渠道的营收占比一路攀升，2025年仅线上电商板块销售额就占到该单品总营收超40%，并连续两年跻身主流平台妇科处方药销售榜前十。但他并未将其当成通用公式全盘复刻——产品的渠道布局，必须经过三重漏斗层层筛选。 “第一重漏斗看临床需求属性：这款药是临床急需的刚需用药，还是可被替代的常规用药，不同的需求等级直接决定了渠道的适配性；第二重漏斗看支付属性，不同的支付规则会直接影响用户的购药路径选择；第三重漏斗才是匹配对应的消费人群、使用场景和用户消费习惯，最终搭建起完全适配这款产品的专属渠道框架。” 二、三大增长引擎：立足商业化品种，挖掘确定性增量与聚焦少数赛道的医药公司逻辑不同，汇伦已上市或即将上市产品横跨呼吸重症、肿瘤、心血管、妇科、男科、泌尿等多个领域。董竹坦诚表示：“今天的产品结构是5—10 年前的决定。”在行业普遍追逐“远期故事性”的当下，董竹的判断很务实：汇伦未来三年的核心增长驱动力，全部来自已上市或即将上市的确定性产品，而非尚在临床阶段的远期创新药。引擎一：阿齐沙坦氨氯地平片(商品名：泰复安®)。“我们的第一个核心增长引擎，就是今年1月刚刚获批的阿齐沙坦氨氯地平片复方高血压药物。”董竹介绍。这款复方降压药为国内首仿。该产品将在院内外渠道同步布局，以患者服务为中心，提供专业化、全周期的用药管理方案，形成院内诊断治疗、院外承接服务的用药管理闭环。引擎二：1mg规格的地诺孕素片(子宫腺肌病适应症)。该产品已提交注册申请，正处于审评阶段，预计于2026年四季度获批。依托已上市2mg产品(子宫内膜异位症适应症)积累的市场基础与KOL资源，其可覆盖的患者基数预计将显著扩大。引擎三：枭雄®男科产品矩阵。公司已形成覆盖阿伐那非、西地那非、他达拉非、达泊西汀(即“三非一汀”)的全场景产品矩阵，还创新推出专利糖果式迷你包装，针对性解决传统男科产品隐私性不足、携带不便、消费者购买尴尬的痛点，凭借小巧隐蔽、便携易用的核心优势，打造出差异化的产品竞争力。此外，已上市的希为纳®(注射用西维来司他钠，是全球唯一获批用于全身性炎症反应综合征相关的急性肺损伤与急性呼吸窘迫综合征的靶向药物)、佐愈®(注射用左亚叶酸)以及其他品种，同样具备增长空间，与三大增长引擎共同构建汇伦近三年的增长曲线。三、管线收拢：只做优势赛道董竹强调，近三年的增长由已上市和即将上市的品种支撑，更远的未来则要交给创新管线接棒。“仿制药能够成长的空间和天花板，大家都已经看得比较清楚了。汇伦积累了这么多年的研发经验，我们有一定的探索能力、技术能力，创新管线要继续往前走。未来汇伦将以创新药作为主要的产品。” 目前，汇伦的自研方向已明显收拢至两大领域。其一是呼吸类，这是希为纳®(注射用西维来司他钠)积累下的“能力圈延伸”，既有可吸入改良型新药 H057，也有全新靶点药物 YD0293——截至2026年7月27日，中国尚无创新型DPP1抑制剂获批，而汇伦的YD0293为全球及中国唯二专门针对CRSsNP的DPP1候选抑制剂之一。其二是神经与镇痛类，核心推进 Nav1.8 抑制剂 HL-1186，这是中国首款进入临床研究、同时靶向急性与慢性疼痛适应症的Nav1.8 抑制剂，旨在解决现有镇痛药物成瘾性、使用周期短、副作用大等临床痛点。在赛道选择上，董竹的回答很务实：一些热门赛道已有大量企业深耕多年，汇伦并未在早期介入，因此不参与这类高强度竞争，而是将资源集中到自身具备积累的优势领域。四、转型样本：重新证明一家药企的价值汇伦医药的转型之路，某种程度上是中国数千家制药企业的缩影。在“缺医少药”的行业早期，靠一款好药、一套渠道就能打下江山；但在医保严管、渠道多元、创新内卷、资本理性的新周期里，则必须用更精细的产品理解、更系统化的渠道运营、更克制的战略聚焦，重新证明一家药企的价值。关于上海汇伦医药股份有限公司汇伦医药成立于 2004 年，是一家覆盖从研发、生产到商业化全产业链的制药公司，重点聚焦重大疾病及危重症领域的创新药物。公司主要已上市产品包括希为纳®(注射用西维来司他钠)、佐愈®(注射用左亚叶酸)、蒂诺安®(地诺孕素片)、康迈瑞®(替格瑞洛片)、利尔班®(利伐沙班片)等，目前已有十余种药物获批上市。

2026-10-07

·新浪看点

上海汇伦医药董竹：不做“放之四海皆准”的渠道，以双渠道协同锚定增长

2026 年的中国医药产业，正站在创新与转型的十字路口：一方面，创新药研发进入集中收获期，国家药监局《2025年度药品审评报告》显示，2025年全年批准1类创新药 76 个，创历史新高；另一方面，药品流通渠道深刻重构，互联网医疗、医药电商、DTP 专业药房等新业态加速分流传统医院终端市场，“院内萎缩就全面转向院外”成为行业热议话题。上海汇伦医药股份有限公司(以下简称“汇伦医药”)执行董事董竹给出的答案，是“两条腿走路”。董竹表示，渠道策略不能一刀切，需要一套多维度筛选漏斗；而未来三年的增长，将锚定多款已上市或即将上市的核心品种。一、从研发到销售：一套渠道方法论的由来这套方法论源自董竹横跨前后端的职业轨迹。2019年加入汇伦医药后，董竹先从临床研究工作做起，随后逐步拓展至企业经营及业务管理。自2024年3月起，他负责公司综合业务部及OTC业务部的整体运营与管理。院外市场彼时刚刚打开，摆在团队面前的路径很多——院外线下门店、社区药店、线上购药平台，资源投入与产出逻辑各不相同。“我们没有盲目跟风行业的普遍路径，通常是站在产品特性和用户特性的角度做分析。”董竹进一步以2mg地诺孕素片为例解释：作为治疗子宫内膜异位症的专科用药，该产品需长期每日服用、可替代性低，天然匹配电商的批量备货与便捷性逻辑；2mg规格的地诺孕素片，核心受众为20—50岁女性，恰是电商消费主力人群。市场验证了这一判断：公司地诺孕素片在院外渠道的营收占比一路攀升，2025年仅线上电商板块销售额就占到该单品总营收超40%，并连续两年跻身主流平台妇科处方药销售榜前十。但他并未将其当成通用公式全盘复刻——产品的渠道布局，必须经过三重漏斗层层筛选。“第一重漏斗看临床需求属性：这款药是临床急需的刚需用药，还是可被替代的常规用药，不同的需求等级直接决定了渠道的适配性；第二重漏斗看支付属性，不同的支付规则会直接影响用户的购药路径选择；第三重漏斗才是匹配对应的消费人群、使用场景和用户消费习惯，最终搭建起完全适配这款产品的专属渠道框架。”二、三大增长引擎：立足商业化品种，挖掘确定性增量与聚焦少数赛道的医药公司逻辑不同，汇伦已上市或即将上市产品横跨呼吸重症、肿瘤、心血管、妇科、男科、泌尿等多个领域。董竹坦诚表示：“今天的产品结构是5—10 年前的决定。”在行业普遍追逐“远期故事性”的当下，董竹的判断很务实：汇伦未来三年的核心增长驱动力，全部来自已上市或即将上市的确定性产品，而非尚在临床阶段的远期创新药。引擎一：阿齐沙坦氨氯地平片(商品名：泰复安®)。“我们的第一个核心增长引擎，就是今年1月刚刚获批的阿齐沙坦氨氯地平片复方高血压药物。”董竹介绍。这款复方降压药为国内首仿。该产品将在院内外渠道同步布局，以患者服务为中心，提供专业化、全周期的用药管理方案，形成院内诊断治疗、院外承接服务的用药管理闭环。引擎二：1mg规格的地诺孕素片(子宫腺肌病适应症)。该产品已提交注册申请，正处于审评阶段，预计于2026年四季度获批。依托已上市2mg产品(子宫内膜异位症适应症)积累的市场基础与KOL资源，其可覆盖的患者基数预计将显著扩大。引擎三：枭雄®男科产品矩阵。公司已形成覆盖阿伐那非、西地那非、他达拉非、达泊西汀(即“三非一汀”)的全场景产品矩阵，还创新推出专利糖果式迷你包装，针对性解决传统男科产品隐私性不足、携带不便、消费者购买尴尬的痛点，凭借小巧隐蔽、便携易用的核心优势，打造出差异化的产品竞争力。此外，已上市的希为纳®(注射用西维来司他钠，是全球唯一获批用于全身性炎症反应综合征相关的急性肺损伤与急性呼吸窘迫综合征的靶向药物)、佐愈®(注射用左亚叶酸)以及其他品种，同样具备增长空间，与三大增长引擎共同构建汇伦近三年的增长曲线。三、管线收拢：只做优势赛道董竹强调，近三年的增长由已上市和即将上市的品种支撑，更远的未来则要交给创新管线接棒。“仿制药能够成长的空间和天花板，大家都已经看得比较清楚了。汇伦积累了这么多年的研发经验，我们有一定的探索能力、技术能力，创新管线要继续往前走。未来汇伦将以创新药作为主要的产品。”目前，汇伦的自研方向已明显收拢至两大领域。其一是呼吸类，这是希为纳®(注射用西维来司他钠)积累下的“能力圈延伸”，既有可吸入改良型新药 H057，也有全新靶点药物 YD0293——截至2026年7月27日，中国尚无创新型DPP1抑制剂获批，而汇伦的YD0293为全球及中国唯二专门针对CRSsNP的DPP1候选抑制剂之一。其二是神经与镇痛类，核心推进 Nav1.8 抑制剂 HL-1186，这是中国首款进入临床研究、同时靶向急性与慢性疼痛适应症的Nav1.8 抑制剂，旨在解决现有镇痛药物成瘾性、使用周期短、副作用大等临床痛点。在赛道选择上，董竹的回答很务实：一些热门赛道已有大量企业深耕多年，汇伦并未在早期介入，因此不参与这类高强度竞争，而是将资源集中到自身具备积累的优势领域。四、转型样本：重新证明一家药企的价值汇伦医药的转型之路，某种程度上是中国数千家制药企业的缩影。在“缺医少药”的行业早期，靠一款好药、一套渠道就能打下江山；但在医保严管、渠道多元、创新内卷、资本理性的新周期里，则必须用更精细的产品理解、更系统化的渠道运营、更克制的战略聚焦，重新证明一家药企的价值。关于上海汇伦医药股份有限公司汇伦医药成立于 2004 年，是一家覆盖从研发、生产到商业化全产业链的制药公司，重点聚焦重大疾病及危重症领域的创新药物。公司主要已上市产品包括希为纳®(注射用西维来司他钠)、佐愈®(注射用左亚叶酸)、蒂诺安®(地诺孕素片)、康迈瑞®(替格瑞洛片)、利尔班®(利伐沙班片)等，目前已有十余种药物获批上市。发布于：江苏

申请上市引进/卖出

2026-10-06

·PRNewswire

Mint Pharmaceuticals Inc. and Bayer Inc. Expand Distribution Partnership in Canada

Expanded collaboration supports continued Canadian access to Bayer medicines across cardiovascular and women's health portfolios. MISSISSAUGA, ON, Oct. 6, 2026 /PRNewswire/ -- Mint Pharmaceuticals Inc. is pleased to announce the expansion of its distribution partnership with Bayer Inc. to include ANGELIQ® (drospirenone and estradiol-17β tablets), CLIMARA® 25, CLIMARA® 50 and CLIMARA® 75 (estradiol hemihydrate transdermal systems), TRIQUILAR® 21 and TRIQUILAR® 28 (levonorgestrel and ethinyl estradiol tablets), and XARELTO® (rivaroxaban granules for oral suspension) in Canada. The expanded collaboration builds on the companies' existing relationship and shared commitment to reliable access to medicines for Canadian patients and healthcare professionals. Continue Reading Olenka Crewe, VP of Business Development & Scientific Affairs, Mint Pharmaceuticals, Jaiveer Singh, CEO, Mint Pharmaceuticals, Viktoria Friedrich, President and CEO of Bayer Inc. in Canada. Jennifer Lloyd, Head of Finance, Pharmaceutical Division, Bayer Inc. (CNW Group/Mint Pharmaceuticals) The partnership was originally established to support the Canadian distribution of Bayer's ADALAT® XL® (nifedipine extended-release tablets), an antihypertensive / antianginal medicine. The addition of ANGELIQ®, CLIMARA®, TRIQUILAR®, and XARELTO® extends the collaboration across a broader range of therapeutic areas while maintaining the companies' focus on dependable supply and continuity of care. "Ensuring Canadian patients and healthcare professionals can rely on consistent access to established medicines is central to Mint's mission," said Jaiveer Singh, Chief Executive Officer of Mint Pharmaceuticals. "Expanding our work with Bayer allows us to apply Mint's resilient supply chain and nationwide distribution capabilities across a broader portfolio, while advancing our mutual focus on reliability, quality and patient care." "We are pleased to expand our partnership with Mint Pharmaceuticals Inc., building on a trusted collaboration rooted in quality, reliability and a shared commitment to patient care," said Viktoria Friedrich, President and CEO of Bayer Inc. in Canada. "By broadening this partnership across additional Bayer medicines, we can continue to leverage Mint's strong Canadian distribution network and market expertise to help ensure these treatments remain accessible to healthcare professionals and patients who rely on them." Through this expanded partnership, Mint Pharmaceuticals and Bayer Inc. aim to maintain high standards of distribution and supply continuity across the portfolio, helping ensure that healthcare professionals and patients across Canada have timely access to these medicines. About Mint Pharmaceuticals Mint Pharmaceuticals is a leading Canadian-owned and operated manufacturer of high-quality, affordable generic medicines. Mint has built one of the strongest and most resilient pharmaceutical supply chains in the country, helping safeguard patient access by averting 25 national drug shortages across 16 essential medicines in the last decade. The company has been recognized by Deloitte as one of Canada's Best Managed Companies for eight consecutive years, achieving Platinum Club status in 2025, and is a member company of the Canadian Generic Pharmaceutical Association (CGPA). About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to . Find more information at and at . SOURCE Mint Pharmaceuticals 21% more press release views with Request a Demo

100 项与利伐沙班相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07086	利伐沙班	B01AF01	DB06228

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
冠状动脉疾病	美国	Janssen Pharmaceuticals, Inc.	2026-03-24
血栓栓塞	日本	Bayer Yakuhin Ltd.	2023-11-24
血栓形成	美国	Janssen Pharmaceuticals, Inc.	2021-12-20
动脉粥样硬化	欧盟	Viatris Ltd. (New Zealand)	2021-11-12
动脉粥样硬化	冰岛	Viatris Ltd. (New Zealand)	2021-11-12
动脉粥样硬化	列支敦士登	Viatris Ltd. (New Zealand)	2021-11-12
动脉粥样硬化	挪威	Viatris Ltd. (New Zealand)	2021-11-12
心房颤动	中国	Bayer AG	2009-03-31
心肌梗塞	澳大利亚	Bayer Australia Ltd.	2008-11-24
复发性深静脉血栓形成	澳大利亚	Bayer Australia Ltd.	2008-11-24
脑卒中	澳大利亚	Bayer Australia Ltd.	2008-11-24
全身性栓塞	澳大利亚	Bayer Australia Ltd.	2008-11-24
急性冠状动脉综合征	欧盟	Bayer AG	2008-09-30
急性冠状动脉综合征	冰岛	Bayer AG	2008-09-30
急性冠状动脉综合征	列支敦士登	Bayer AG	2008-09-30
急性冠状动脉综合征	挪威	Bayer AG	2008-09-30
急性冠状动脉综合征	英国	Bayer Plc	2008-09-30
栓塞	欧盟	Bayer AG	2008-09-30
栓塞	冰岛	Bayer AG	2008-09-30
栓塞	列支敦士登	Bayer AG	2008-09-30

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心血管疾病	临床3期	澳大利亚	Bayer AG	2021-01-18
心血管疾病	临床3期	比利时	Bayer AG	2021-01-18
心血管疾病	临床3期	加拿大	Bayer AG	2021-01-18
心血管疾病	临床3期	法国	Bayer AG	2021-01-18
心血管疾病	临床3期	德国	Bayer AG	2021-01-18
心血管疾病	临床3期	印度	Bayer AG	2021-01-18
心血管疾病	临床3期	马来西亚	Bayer AG	2021-01-18
心血管疾病	临床3期	尼泊尔	Bayer AG	2021-01-18
心血管疾病	临床3期	沙特阿拉伯	Bayer AG	2021-01-18
心血管疾病	临床3期	新加坡	Bayer AG	2021-01-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05797376 (Pubmed \| Eur Heart J Cardiovasc Imaging)	临床2期	颈动脉疾病	92	Aspirin plus low-dose rivaroxaban	襯齋鏇窪構鏇願網膚築(壓憲選選糧夢願襯廠艱) = 窪衊窪餘觸艱壓淵鏇餘壓顧憲窪衊製壓獵鹽鬱 (簾糧糧築顧顧糧窪艱鑰 )	不佳	2026-09-01
				Aspirin alone	襯齋鏇窪構鏇願網膚築(壓憲選選糧夢願襯廠艱) = 憲鹹遞築鏇蓋製鹹壓醖壓顧憲窪衊製壓獵鹽鬱 (簾糧糧築顧顧糧窪艱鑰 )
ESC2026	N/A	心房颤动	115,040	On-label DOAC dosing	顧鹽膚窪觸築蓋餘觸繭(選壓憲觸廠觸醖顧淵獵) = 糧衊蓋夢鑰蓋蓋膚鹽衊齋製獵遞製繭構築餘衊 (簾鑰襯鹹艱簾築簾憲廠 ) 更多	积极	2026-08-28
				Off-label DOAC dosing	顧鹽膚窪觸築蓋餘觸繭(選壓憲觸廠觸醖顧淵獵) = 醖淵壓憲築淵構鑰鏇憲齋製獵遞製繭構築餘衊 (簾鑰襯鹹艱簾築簾憲廠 ) 更多
NCT05546320 (Pubmed \| BMJ)	临床2期	偏头痛	984	Aspirin 300 mg once daily	膚淵餘願觸膚觸製蓋糧(製鹹構遞鬱糧鹽範淵壓) = 淵憲淵繭憲選鏇廠範鹽鏇築顧憲醖襯糧觸襯蓋 (築獵窪鏇遞廠夢築夢艱 )	积极	2026-07-29
				Clopidogrel 75 mg once daily	膚淵餘願觸膚觸製蓋糧(製鹹構遞鬱糧鹽範淵壓) = 醖窪鏇鏇範蓋築簾範襯鏇築顧憲醖襯糧觸襯蓋 (築獵窪鏇遞廠夢築夢艱 )
NCT03969953 (Pubmed \| JAMA)	临床3期	肾脏疾病	1,458	Rivaroxaban 2.5 mg	夢鹹憲憲築艱蓋衊餘鏇(遞構膚襯餘艱遞獵窪壓) = 齋蓋鬱構襯壓淵網醖獵網範構鏇糧膚觸淵願築 (鏇鏇築築夢遞淵廠壓淵 ) 更多	不佳	2026-07-28
				Placebo	夢鹹憲憲築艱蓋衊餘鏇(遞構膚襯餘艱遞獵窪壓) = 糧窪積壓膚鹹淵獵顧窪網範構鏇糧膚觸淵願築 (鏇鏇築築夢遞淵廠壓淵 ) 更多
ISTH2026	N/A	短肠综合征	20	Rivaroxaban	構醖襯鏇顧獵襯齋製糧(餘簾範夢餘獵襯願獵簾) = 窪築鑰鏇網鹹遞築艱憲鏇鏇範繭襯繭遞蓋憲築 (襯鏇艱鏇遞構鏇壓壓壓, 41 ~ 206) 更多	积极	2026-07-13
ISTH2026	N/A	-	205	Rivaroxaban 10mg daily	齋鑰淵選鏇觸繭網餘願(鏇齋網築觸遞顧鹽簾餘) = 構窪築顧鬱衊齋製醖鑰鏇餘艱糧鑰壓窪鹹襯製 (選壓艱獵鏇遞觸選積夢 ) 更多	积极	2026-07-13
ISTH2026	N/A	血栓形成	34	Direct oral anticoagulants (DOACs)	齋憲構齋築餘積繭遞顧(淵鹹遞網糧積襯鹽築窪) = 壓衊鹽淵遞醖淵繭範築鑰鏇觸鑰壓艱蓋廠鑰鬱 (範淵蓋餘襯衊壓範膚築 ) 更多	积极	2026-07-13
ISTH2026	N/A	静脉血栓栓塞	57	Rivaroxaban (VTE treatment)	鑰範憲鹽膚齋簾遞憲鹹(鑰獵淵鹽遞鏇壓餘繭願) = 獵鑰構淵壓淵夢網範齋製簾製鹹憲構簾網鹽廠 (淵範鬱構觸窪製襯餘範 )	积极	2026-07-13
ISTH2026	N/A	多发性骨髓瘤	20	Low-dose aspirin	糧鬱鏇齋築簾淵夢獵淵(襯構壓觸齋鏇糧夢窪製) = 窪製窪艱壓選網醖鏇鑰糧觸鹹淵築艱製襯襯繭 (簾襯糧鏇築鏇艱鏇襯膚 )	积极	2026-07-13
				DOACs (rivaroxaban 15-20 mg OD)	簾獵壓膚窪構夢簾壓醖(願鑰築壓範範願範艱繭) = 簾觸鬱蓋觸鹽觸選淵蓋鬱餘獵顧窪遞夢鏇鹽衊 (襯壓築糧範蓋蓋憲襯網 )
ISTH2026	N/A	血栓形成	60	Apixaban	齋鏇鏇鹹獵襯構蓋醖繭(膚積鏇繭窪願廠齋糧範) = 壓鑰遞鑰鹹憲構餘憲壓艱網壓簾鹹壓積簾範鏇 (築膚壓築繭遞製衊網鏇 ) 更多	积极	2026-07-13